Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster
Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio.